Long-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue.
Reference facts
- Also known as
- Lantus, Toujeo, Basaglar
- Category
- Hormonal & Pituitary
- Mechanism of action
- Long-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue.
- Targets
- Insulin receptor
- Indications under research or approved
- Diabetes type 1 and 2 — basal insulin replacement
- Regulatory status (reference entry)
- FDA-approved (2000)
- Half-life
- ~12 hours (effective duration ~24 hours)
- Sequence
- GIVEQCCTSICSLYQLENYCG
- Sequence notes
- Modified insulin: A-chain Asn21 → Gly; B-chain extended with Arg-Arg at C-terminus, forming microprecipitates at neutral subcutaneous pH for prolonged release.
- Molecular weight (Da)
- 6063
- Originator / sponsor
- Sanofi (Lantus); Eli Lilly (Basaglar biosimilar)
- First reported
- 1996
Primary References
Explore research articles about Insulin Glargine
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.